influenza
vaccin
administ
intranas
needlefre
deliveri
rout
potenti
advantag
inject
formul
term
patient
complianc
cost
eas
global
distribut
supramolecular
peptid
nanofib
investig
previous
platform
vaccin
immunotherapi
shown
rais
immun
respons
absenc
exogen
adjuv
without
measur
inflamm
howev
present
test
whether
immunogen
materi
extend
intranas
rout
investig
extent
selfassembl
peptid
nanofib
bear
influenza
peptid
epitop
elicit
antigenspecif
cell
respons
deliv
intranas
compar
respons
elicit
subcutan
immun
peptid
contain
epitop
influenza
acid
polymeras
pa
selfassembl
domain
form
nanofib
avidli
taken
dendrit
cell
lungdrain
mediastin
lymph
node
intranas
immun
intranas
deliv
nanofib
gener
greater
antigenspecif
cell
respons
lungdrain
lymph
node
subcutan
immun
retain
noninflammatori
charact
materi
observ
deliveri
site
cell
elicit
system
function
assess
abil
produc
ex
vivo
lyse
epitopepuls
target
cell
vivo
diminish
viral
load
infect
mice
compar
subcutan
deliv
nanofib
intranas
deliv
peptid
nanofib
significantli
increas
number
persist
antigenspecif
tissu
resid
memori
cell
lung
allow
rapid
respons
infect
week
postvaccin
result
indic
intranas
deliv
selfassembl
peptid
nanofib
immunogen
deliv
epitop
without
adjuv
epitop
noninflammatori
promot
lungresid
memori
cell
compar
subcutan
immun
influenza
signific
problem
global
health
vaccin
promis
mean
diminish
impact
improv
patient
complianc
global
access
needlefre
immun
system
receiv
consider
interest
annual
season
influenza
vaccin
recommend
unit
state
center
diseas
control
prevent
nasal
administ
liveattenu
vaccin
flumist
astrazeneca
recommend
past
two
season
efficaci
found
inferior
inject
trival
inactiv
viru
tiv
formul
transcriptom
analysi
reveal
intranas
vaccin
tiv
vaccin
induc
differ
gene
signatur
tiv
vaccin
induc
gene
associ
b
cellantibodi
respons
intranas
vaccin
elicit
enrich
gene
highli
express
cell
monocyt
mechan
lead
differenti
immun
respons
vari
efficaci
remain
fulli
investig
nevertheless
observ
underscor
need
improv
nasal
administ
vaccin
particular
vaccin
capabl
elicit
strong
cytotox
cell
respons
tissu
resid
memori
cell
rm
lung
would
advantag
vaccin
could
offer
rapid
clearanc
influenza
viru
upon
subsequ
exposur
possibl
broad
protect
instanc
stamba
et
al
demonstr
cell
puls
peptid
nucleoprotein
np
asnenmetm
acid
polymeras
pa
sslenfrayv
abl
clear
multipl
strain
influenza
viru
cell
numberdepend
manner
supramolecular
peptid
nanofib
receiv
interest
recent
vaccin
immunotherapi
applic
rang
infecti
diseas
drug
addict
chronic
inflamm
cancer
mani
case
nanofib
requir
supplement
adjuv
immunogen
exampl
peptid
protein
nanoparticl
vaccin
deliv
intranas
exist
literatur
supramolecular
peptid
nanofib
yet
studi
systemat
context
intranas
deliveri
leav
open
question
whether
nanofib
retain
intrins
immunogen
rout
whether
immun
respons
elicit
differ
significantli
elicit
inject
formul
among
advantag
supramolecular
peptid
vaccin
chemic
definit
modular
afford
noncoval
construct
minim
inflammatori
natur
togeth
properti
allow
adjust
strength
phenotyp
immun
respons
rais
nanofib
formul
achiev
straightforward
manner
synthes
peptid
epitop
select
antigen
tandem
selfassembl
peptid
form
peptid
fibril
peptid
subcutan
inject
supramolecular
nanofib
stimul
strong
cytotox
cell
respons
without
adjuv
recent
rudra
group
show
nanofib
carri
ovalbumin
siinfekl
epitop
abl
elicit
siinfeklspecif
cell
without
adjuv
vaccin
mice
abl
maintain
bodi
weight
follow
subleth
influenza
challeng
use
influenza
viru
studi
booster
immun
administ
intranas
primari
immun
administ
via
inject
ding
et
al
report
epitop
hiv
slyntvatl
conjug
selfassembl
peptid
induc
antigenspecif
tcell
respons
codeliv
tlr
agonist
anoth
report
indic
influenza
viruslik
particl
contain
express
hemagglutinin
ha
matrix
protein
abl
stimul
haspecif
tcell
respons
intranas
deliveri
togeth
previou
studi
suggest
adjuvantfre
peptid
nanofib
contain
influenza
peptid
epitop
may
abl
elicit
tcell
respons
lung
intranas
prime
boost
hypothesi
test
explor
peptid
nanofib
intranas
influenza
vaccin
synthes
peptid
contain
selfassembl
domain
cterminu
conserv
pa
epitop
pa
sslenfrayv
acid
polymeras
influenza
apr
viru
nterminu
formul
contain
addit
epitop
pa
epitop
chosen
report
adopt
transfer
paspecif
cell
abl
clear
viru
mice
track
uptak
nanofib
drain
mediastin
lymph
node
studi
antigen
crosspresent
anoth
cell
epitop
sinnfekl
vitro
use
report
cell
line
next
evalu
recruit
inflammatori
cell
product
inflammatori
cytokin
lung
intranas
administr
importantli
compar
system
lungresid
tcell
respons
intranas
subcutan
rout
studi
abil
vaccin
mice
control
viru
infect
lung
first
report
knowledg
elicit
lungresid
tcell
respons
use
intranas
deliv
peptid
nanofib
without
adjuv
depend
cell
epitop
h
nsiinfeklsgsg
qqkfqfqfeqqam
synthes
use
standard
fmoc
solid
phase
synthesi
csbio
peptid
synthes
peptid
ident
confirm
maldi
peptid
purifi
revers
phase
hplc
lyophil
store
use
enabl
detect
nanofib
uptak
flow
cytometri
carboxytetramethylrhodamin
tamra
conjug
synthes
via
ntermin
onresin
conjug
use
carbodiimid
edc
coupl
prepar
nanofib
dri
peptid
combin
final
nanofib
formul
contain
mm
uptak
present
studi
mm
dri
powder
intermix
vortex
dissolv
ultrapur
water
concentr
mm
total
peptid
final
concentr
overnight
incub
peptid
solut
dilut
mm
pb
use
ultrapur
water
pb
addit
pb
induc
final
fibril
product
result
nanofib
contain
mm
peptid
incub
room
temperatur
h
use
endotoxin
level
measur
use
limulu
amebocyt
lysat
chromogen
endpoint
assay
lonza
allendal
nj
usa
endotoxin
level
formul
euml
within
accept
limit
vivo
anim
studi
uptak
studi
nanofib
contain
mm
fluoresc
shear
nanofib
prepar
pass
membran
use
avanti
mini
extrud
method
reduc
length
nanofib
hundr
nanomet
long
averag
nm
nanofib
morpholog
character
transmiss
electron
microscopi
tem
nanofib
formul
dilut
mm
pb
deposit
onto
formvarcarbonco
copper
grid
electron
microscopi
scienc
min
incub
grid
wash
water
stain
wv
uranyl
acet
water
min
excess
liquid
wick
away
filter
paper
grid
airdri
imag
fei
tecnai
tem
mice
week
age
purchas
harlanenvigo
laboratori
charl
river
laboratori
mice
hous
central
anim
facil
procedur
perform
approv
institut
anim
care
use
committe
univers
chicago
duke
univers
mice
anesthet
vaccin
formul
mm
total
peptid
administ
one
nostril
use
micropipett
mice
boost
formul
week
unless
note
otherwis
volum
consist
previou
report
literatur
solut
administ
intranas
addit
administr
volum
major
materi
shown
distribut
lung
minim
amount
distribut
stomach
subcutan
immun
mice
anesthet
isofluran
administ
two
inject
mm
peptid
one
left
right
flank
booster
immun
given
week
primari
immun
dose
uptak
inflamm
evalu
duke
univers
tcell
respons
protect
assess
univers
chicago
influenza
viru
strain
stock
kind
gift
david
j
topham
univers
rochest
virus
prepar
lethal
dose
determin
univers
chicago
infect
naiv
mice
rang
dose
anesthet
mice
challeng
subleth
dose
virus
administr
viru
suspens
dilut
pb
twenti
hour
intranas
deliveri
tamralabel
nanofib
drain
mediastin
lymph
node
collect
singlecel
suspens
prepar
press
node
cell
strainer
cell
stain
mhcii
cat
biolegend
cat
biolegend
cat
bd
bioscienc
cat
biolegend
analyz
bd
canto
flow
cytomet
dc
gate
mhcii
high
studi
present
vitro
report
cell
line
use
mous
brestrict
ctl
hybridoma
specif
ova
siinfekl
epitop
produc
upon
recognit
siinfekl
present
mhci
bone
marrow
deriv
dendrit
cell
bmdc
cultur
complet
rpmi
medium
supplement
l
thermo
fisher
cat
loos
bound
cell
float
cell
collect
day
experi
cellsml
bmdc
ad
well
follow
solubl
peptid
peptid
nanofib
serial
dilut
concentr
incub
predetermin
period
time
plate
centrifug
min
wash
pb
twice
altern
bmdc
fix
formaldehyd
min
room
temperatur
wash
pb
treat
mm
peptid
nanofib
wash
plate
supernat
aspir
cellsml
cell
ad
well
atop
bmdc
plate
incub
co
incub
overnight
plate
centrifug
min
wash
pb
twice
supernat
aspir
freshli
prepar
lacz
buffer
vv
igepac
mm
mgcl
mm
mm
chlorophenol
red
betagalactosid
pb
ad
well
incub
h
absorb
nm
nm
refer
record
plate
reader
evalu
recruit
proinflammatori
cell
product
proinflammatori
cytokin
lung
bronchoalveolar
lavag
fluid
balf
lung
collect
h
intranas
administr
peptid
vaccin
equal
volum
pb
employ
noninflammatori
control
equal
volum
mgml
lp
pb
sigma
cat
use
inflammatori
control
concentr
gmcsf
tnf
balf
measur
use
mous
inflammatori
magnet
panel
life
technolog
cat
follow
manufactur
instruct
lung
tissu
dissect
digest
mgml
collagenas
iv
dnase
min
tissu
filter
cell
strainer
cell
treat
ml
ammoniumchloridepotassium
ack
lyse
buffer
thermo
fisher
cat
min
room
temperatur
neutral
ml
flow
buffer
pass
cell
strainer
centrifug
cell
pellet
resuspend
flow
buffer
stain
mhcii
cat
bd
bioscienc
cat
biolegend
cat
biolegend
data
analyz
flow
jo
previous
report
spleen
collect
mice
intranas
vaccin
boost
singlecel
suspens
prepar
plate
cell
per
well
plate
millipor
cat
precoat
antimous
captur
antibodi
bd
bioscienc
cat
cell
stimul
solubl
pa
peptid
left
untreat
neg
control
co
incub
h
detect
secret
cell
spot
detect
antibodi
bd
bioscienc
cat
streptavidinalkalin
phosphatas
mabtech
cat
substrat
sigmafast
bcipnbt
sigma
cat
appli
sequenti
follow
manufactur
protocol
plate
imag
spot
count
use
elispot
reader
cellular
technolog
ltd
splenocyt
harvest
naiv
mice
red
blood
cell
lyse
follow
wash
pb
twice
cell
count
divid
two
popul
one
popul
puls
pa
peptid
incub
h
label
low
concentr
cfse
cfse
lo
invitrogen
cat
second
popul
puls
irrelev
peptid
control
np
asnenmetm
label
high
concentr
cfse
cfse
hi
equal
number
cfse
hi
cfse
lo
cell
mix
cell
inject
intraven
mice
intranas
vaccin
unimmun
h
mice
sacrif
spleen
remov
singlecel
suspens
gener
cfselabel
cell
enumer
lsrii
flow
cytomet
percent
kill
calcul
follow
percent
cfse
lo
immun
mice
cfse
hi
immun
mice
percent
cfse
lo
naiv
mice
cfse
hi
naiv
mice
number
viral
rna
copi
per
lung
determin
quantit
rtpcr
rna
prepar
wholelung
homogen
use
rneasi
mini
kit
qiagen
cat
follow
manufactur
direct
quantit
pcr
conduct
amplifi
gene
viru
use
superscript
iii
platinum
sybr
green
onestep
qrtpcr
kit
invitrogen
cat
reaction
normal
housekeep
gene
primer
use
studi
forward
revers
forward
revers
fig
negativestain
tem
illustr
fiber
morpholog
shown
nanofib
compos
mm
total
peptid
contain
mm
epitopebear
peptid
indic
mm
ratio
nanofib
dilut
mm
pb
immedi
prior
applic
onto
grid
view
tem
scale
bar
appli
panel
naiv
vaccin
mice
inject
intraven
antibodi
clone
cat
thermo
fisher
min
lung
harvest
lymphocyt
isol
flow
cytometr
analysi
previous
describ
sampl
block
incub
min
pa
b
tetram
produc
nih
tetram
core
facil
emori
univers
atlanta
ga
room
temperatur
dark
cell
prepar
flow
cytometri
use
aquafluor
livedead
solut
thermo
fisher
cat
exclud
dead
cell
cocktail
dump
antibodi
use
exclud
un
antibodi
purchas
ebiosci
unless
specifi
tissueloc
cell
design
bloodborn
cell
tissu
resid
memoryeffector
cell
identifi
cell
antigenspecif
memoryeffector
cell
identifi
pa
b
tetram
cell
flow
cytometri
perform
lsrii
fortessa
bd
analyz
flowjo
softwar
data
present
mean
standard
deviat
statist
analys
perform
use
graphpad
prism
softwar
differ
group
analyz
use
oneway
twoway
anova
student
ttest
appropri
indic
figur
caption
abil
selfassembl
peptid
nanofib
elicit
strong
immun
respons
via
subcutan
rout
requir
fibril
confirm
fibril
peptid
studi
use
tem
imag
nanofib
compris
mm
total
peptid
mm
epitopebear
peptid
mm
ratio
vitro
siinfekl
deliv
solubl
peptid
nanofib
crosspres
bmdc
dosedepend
manner
detect
hybridoma
cell
specif
recogn
siinfekl
present
mhci
b
c
data
shown
combin
two
independ
experi
n
pb
n
nanofib
solubl
epitop
b
one
repres
experi
repeat
shown
c
data
present
mean
sd
statist
signific
test
oneway
anova
tukey
multipl
comparison
p
employ
facilit
complet
fibril
consist
previou
observ
variou
epitop
investig
system
form
uniform
nanofib
intermix
fig
next
investig
uptak
nanofib
bear
epitop
intranas
administr
tamralabel
nanofib
averag
mhcii
high
dendrit
cell
dc
drain
mediastin
lymph
node
acquir
label
nanofib
tamraposit
fig
b
previou
studi
nanofib
uptak
intraperiton
inject
determin
tamraposit
dc
intern
label
peptid
rather
mere
bind
surfac
contrast
peptid
nanofib
tamralabel
solubl
epitop
peptid
result
detect
tamraposit
cell
drain
mediastin
lymph
node
possibl
quickli
degrad
peptid
nanofib
uptak
observ
dc
balf
lung
either
group
data
shown
consist
possibl
nanofib
drain
taken
dc
mediastin
lymph
node
although
possibl
intranas
administ
materi
reach
stomach
taken
apc
nasal
mucosa
detect
uptak
nanofib
apc
lungdrain
mediastin
lymph
node
indic
consider
proport
reach
lung
class
mhc
present
epitop
deliv
via
nanofib
studi
vitro
use
bmdc
ctl
hybridoma
report
cell
line
produc
upon
recognit
siinfekl
present
mhci
b
incub
bmdc
nanofiberbound
siinfekl
solubl
siinfekl
present
abl
stimul
cell
concentrationdepend
manner
fig
halfmaxim
load
present
siinfekl
occur
concentr
nm
pm
solubl
siinfekl
expect
low
concentr
solubl
fig
intranas
immun
produc
higher
paspecif
cell
respons
lungdrain
mediastin
lymph
node
compar
subcutan
inject
mice
intranas
subcutan
vaccin
drain
lymph
node
dln
spleen
collect
secondari
immun
antigenspecif
memoryeffector
cell
identifi
pa
tetram
cell
repres
flow
cytometri
plot
display
paspecif
effectormemori
phenotyp
cell
dln
top
spleen
bottom
percentag
paspecif
cell
dln
b
spleen
c
group
size
six
b
twelv
c
mice
least
two
independ
experi
combin
p
p
dose
sc
administr
mm
peptid
day
day
peptid
load
directli
onto
b
wherea
fibril
nanofib
intern
process
siinfekl
present
could
occur
close
bind
pocket
mhci
leav
littl
opportun
exogen
load
peptid
epitop
trim
appropri
amino
acid
length
taken
togeth
vivo
experi
indic
intranas
administ
nanofib
effici
deliv
attach
epitop
dc
drain
lymph
node
vitro
experi
indic
peptid
nanofib
could
process
crosspres
dc
antigenspecif
cell
previou
studi
shown
vaccin
elicit
strong
antibodi
respons
tcell
respons
tcell
respons
inject
subcutan
studi
extent
platform
display
singl
influenzaderiv
epitop
induc
specif
cell
compar
intranas
subcutan
rout
deliveri
chose
epitop
sslenfrayv
linear
b
restrict
epitop
influenza
polymeras
acid
protein
pa
refer
peptid
epitop
pa
selfassembl
peptid
sslenfrayvsgsgqqkfqfqfekk
nanofib
elicit
strong
paspecif
cell
respons
via
either
subcutan
intranas
vaccin
fig
wherea
subcutan
deliv
nanofib
induc
stronger
respons
spleen
fig
c
intranas
administ
nanofib
induc
consider
stronger
respons
lungdrain
mediastin
lymph
node
fig
b
next
explor
whether
nanofib
display
pa
epitop
critic
intranas
immunogen
investig
function
cell
elicit
mice
intranas
immun
nanofib
solubl
pa
peptid
nanofib
nanofib
shear
render
short
assembl
pass
filter
mini
extrud
apparatu
mediastin
lymph
node
collect
paspecif
cell
respons
quantifi
use
pa
b
tetram
primari
immun
shown
fig
shear
nanofib
abolish
product
paspecif
cell
confirm
integr
nanofib
critic
immunogen
via
intranas
rout
addit
support
find
detect
paspecif
cell
observ
intranas
immun
solubl
pa
peptid
fig
lack
pa
epitop
also
shown
previous
nonimmunogen
lack
compet
epitop
attach
nanofib
mix
solubl
peptid
epitop
likewis
nonimmunogen
illustr
complet
form
nanofib
attach
epitop
like
necessari
immunogen
observ
intranas
result
indic
extend
pa
epitop
ctermin
domain
selfassembl
peptid
nanofib
enabl
rais
epitopespecif
respons
lungdrain
lymph
node
without
addit
adjuv
import
antivir
protect
abil
respond
cell
lyse
infect
cell
investig
whether
elicit
paspecif
cell
abl
respond
pa
epitop
produc
mice
sacrif
secondari
immun
elispot
assay
perform
spleenderiv
cell
splenocyt
use
rather
lymph
node
cell
ensur
suffici
cell
number
experi
shown
fig
signific
number
produc
paspecif
cell
detect
spleen
immun
mice
compar
mice
assess
lytic
potenti
effector
paspecif
cell
cytotox
lymphocyt
ctl
immun
mice
vivo
inject
spleen
cell
puls
pa
control
peptid
vaccin
mice
result
vivo
cytotox
assay
consist
elispot
assay
immun
gener
elev
ctl
function
papuls
control
peptidepuls
target
compar
control
mice
immun
fig
also
assess
protect
capac
effector
paspecif
cell
gener
intranas
vaccin
mice
challeng
subleth
dose
influenza
viru
secondari
immun
viral
titer
lung
quantifi
qrtpcr
postchalleng
mice
intranas
vaccin
exhibit
reduct
viral
load
lung
fig
taken
togeth
result
indic
intranas
vaccin
elicit
function
paspecif
respons
vivo
previous
peptid
nanofib
report
minim
inflammatori
intraperiton
footpad
inject
inflammatori
properti
yet
studi
context
intranas
deliveri
investig
inflammatori
cell
infiltr
cytokin
product
intranas
administr
use
pb
lp
noninflammatori
proinflammatori
control
respect
nanofib
elicit
neglig
infiltr
neutrophil
eosinophil
lung
compar
administr
pb
fig
b
wherea
lp
elicit
consider
neutrophil
eosinophil
infiltr
consist
find
elicit
detect
gmcsf
tnf
bronchoalveolar
lavag
fluid
balf
cytokin
level
undistinguish
neg
control
pb
inject
contrast
lp
induc
consider
product
tnf
fig
base
result
conclud
nanofib
deem
minim
inflammatori
lung
consist
previou
find
site
deliveri
also
note
investig
inflammatori
respons
nasal
mucosa
lung
nanofib
minim
inflammatori
nanofib
lp
pb
administ
intranas
mice
inflammatori
cell
cytokin
measur
balf
h
later
flow
cytometri
multiplex
elisa
respect
data
shown
combin
three
independ
experi
total
n
lp
n
nanofib
pb
mean
sd
shown
statist
signific
test
twoway
anova
tukey
multipl
comparison
p
ns
signific
dose
one
administr
mm
peptid
rule
possibl
degre
inflamm
occur
howev
find
would
surpris
given
previou
investig
illustr
inflamm
deliveri
site
ip
sc
next
investig
product
tissueresid
paspecif
cell
lung
use
intravascular
stain
method
exclus
label
circul
cell
blood
tissueloc
cell
mice
vaccin
intranas
subcutan
boost
later
cell
respons
evalu
lung
boost
ten
minut
prior
kill
mice
inject
intraven
conjug
antibodi
bloodborn
cell
immedi
avail
label
procedur
label
wherea
tissueresid
cell
protect
antibodi
label
within
timefram
label
antibodi
thu
pa
antigenspecif
cell
design
tissu
resid
tr
cell
found
intranas
administ
induc
significantli
greater
frequenc
absolut
number
cell
lung
compar
subcutan
administr
fig
b
addit
paspecif
cell
present
within
tr
popul
compar
circul
popul
cell
mice
intranas
immun
fig
next
determin
whether
induc
tr
paspecif
cell
express
earli
activ
marker
typic
tissu
resid
memori
cell
rm
significantli
greater
frequenc
absolut
number
hi
rm
cell
present
intranas
immun
mice
compar
subcutan
immun
mice
fig
f
collect
result
demonstr
intranas
vaccin
establish
robust
tr
paspecif
cell
respons
lung
wherea
subcutan
immun
materi
abl
achiev
result
intranas
immun
gener
paspecif
tissueresid
memori
cell
persist
lung
respond
quickli
system
memori
cell
upon
influenza
infect
tissueresid
memori
rm
cell
shown
respond
rapidli
antigen
upon
challeng
therefor
investig
whether
intranas
vaccin
gener
rm
paspecif
cell
whether
cell
could
persist
lung
vaccin
provid
earlier
antivir
tcell
respons
upon
challeng
mice
challeng
week
nanofib
cell
popul
lung
measur
infect
day
infect
panel
repres
six
mice
least
two
independ
experi
p
p
p
p
ns
signific
twoway
anova
dose
sc
administr
mm
peptid
day
day
day
infect
day
week
immun
prior
challeng
significantli
increas
number
lung
rm
paspecif
cell
detect
fig
day
indic
nanofib
gener
longterm
rm
paspecif
cell
lung
challeng
rm
cell
expans
observ
intranas
immun
mice
subcutan
immun
mice
fig
respons
observ
earli
h
challeng
becam
stronger
h
data
suggest
rm
paspecif
cell
gener
vaccin
persist
lung
respond
rapidli
influenza
infect
prior
studi
known
whether
unadjuv
supramolecular
assembl
peptid
rais
use
tissueresid
memori
cell
respons
deliv
sole
intranas
rout
report
peptid
nanofib
present
influenza
epitop
rais
cell
epitop
intranas
administr
elicit
improv
product
rm
cell
compar
subcutan
inject
part
appear
due
readili
access
lungdrain
mediastin
lymph
node
import
advantag
selfassembl
peptid
system
subunit
vaccin
contain
exogen
adjuv
panel
repres
five
mice
least
two
independ
experi
p
p
p
ns
signific
onetail
ttest
minim
inflammatori
previou
investig
report
peptid
assembl
inflammatori
rout
whether
compos
nanofib
nanofib
prior
studi
perform
subcutan
footpad
intraperiton
deliveri
rout
peptid
nanofib
continu
exhibit
noninflammatori
charact
intranas
deliveri
impress
observ
given
lung
exquisit
sensit
particul
matter
trigger
inflammatori
respons
advers
pulmonari
event
find
also
import
potenti
clinic
develop
supramolecular
peptid
assembl
adjuv
system
engag
inflammatori
pathway
tolllik
receptor
signal
inflammasom
avoid
exogen
adjuv
relianc
short
synthet
peptid
may
also
provid
materi
enhanc
thermal
stabil
also
key
import
vaccin
immunotherapi
develop
world
despit
avoid
use
adjuv
intranas
nevertheless
gener
rm
respons
without
need
thelper
epitop
thu
presum
independ
cell
help
unexpect
find
sinc
cell
activ
absenc
cell
help
develop
memori
cell
undergo
clonal
prolifer
upon
secondari
challeng
furthermor
laidlaw
et
al
report
cell
also
necessari
develop
rm
influenza
infect
mice
contrast
show
immun
without
cell
epitop
without
adjuv
still
elicit
function
rm
memori
cell
expand
rapidli
upon
intranas
influenza
infect
final
show
respons
local
lung
rm
respons
within
lung
consider
superior
intranas
deliv
nanofib
subcutan
vaccin
result
stronger
system
respons
although
present
studi
focus
influenza
combin
induc
rm
respons
without
signific
inflamm
may
also
benefit
vaccin
respiratori
infecti
diseas
group
streptococcu
corona
virus
hantaviru
other
implement
intranas
approach
would
involv
identif
compet
epitop
either
singli
combin
optim
dose
stoichiometri
investig
one
short
mhci
restrict
peptid
epitop
influenza
acid
polymeras
pa
shown
limit
protect
potenc
subsequ
work
supramolecular
peptid
platform
could
extend
incorpor
multipl
epitop
tcell
epitopebcel
epitop
combin
shown
previous
function
well
system
coil
system
would
also
interest
investig
whether
addit
tcell
help
provid
coassembl
strong
promiscu
epitop
would
augment
respons
elicit
addit
b
cell
epitop
addit
epitop
could
envis
augment
vaccin
protect
efficaci
saw
modestli
improv
clearanc
influenza
infect
immun
may
fruit
strategi
develop
peptid
nanofib
bear
epitop
influenza
found
immunogen
via
intranas
rout
compar
subcutan
inject
intranas
deliv
peptid
nanofib
produc
greater
cell
respons
lungdrain
lymph
node
greater
number
tissu
resid
cell
rapid
tissu
resid
memori
respons
influenza
infect
intranas
administr
immunolog
outcom
achiev
without
measur
inflamm
lung
